Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interaction of imatinib with human organic ion carriers.
Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. Hu S, et al. Among authors: hu c. Clin Cancer Res. 2008 May 15;14(10):3141-8. doi: 10.1158/1078-0432.CCR-07-4913. Clin Cancer Res. 2008. PMID: 18483382 Free article.
Pharmacogenetic pathway analysis of docetaxel elimination.
Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Baker SD, et al. Among authors: hu s. Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28. Clin Pharmacol Ther. 2009. PMID: 18509327 Free PMC article.
Pharmacokinetic considerations for new targeted therapies.
Baker SD, Hu S. Baker SD, et al. Among authors: hu s. Clin Pharmacol Ther. 2009 Feb;85(2):208-11. doi: 10.1038/clpt.2008.242. Epub 2008 Dec 17. Clin Pharmacol Ther. 2009. PMID: 19092780 Free PMC article. Review.
Inhibition of OCTN2-mediated transport of carnitine by etoposide.
Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, Baker SD, Sparreboom A. Hu C, et al. Among authors: hu s. Mol Cancer Ther. 2012 Apr;11(4):921-9. doi: 10.1158/1535-7163.MCT-11-0980. Epub 2012 Mar 2. Mol Cancer Ther. 2012. PMID: 22389472 Free PMC article.
OATP1B1 polymorphism as a determinant of erythromycin disposition.
Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. Lancaster CS, et al. Among authors: hu s. Clin Pharmacol Ther. 2012 Nov;92(5):642-50. doi: 10.1038/clpt.2012.106. Epub 2012 Sep 19. Clin Pharmacol Ther. 2012. PMID: 22990751 Free PMC article. Clinical Trial.
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM. Navid F, et al. Among authors: hu s. Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8. Clin Cancer Res. 2013. PMID: 23143218 Free PMC article. Clinical Trial.
17,234 results
You have reached the last available page of results. Please see the User Guide for more information.